Normal QTc for Adult Females
The normal QTc interval for adult females is less than 460 ms, with values of 460 ms or longer considered prolonged. 122
Key Clinical Thresholds
Based on the AHA/ACCF/HRS consensus guidelines, the following cutoffs apply for adult women:
- Normal QTc: < 460 ms
- Prolonged QTc: ≥ 460 ms
- Short QTc: ≤ 390 ms (applies to both sexes)
Important Gender and Age Considerations
Women have physiologically longer QTc intervals than men, with this difference emerging during adolescence when testosterone shortens the QT interval in males but not in females. 12
The gender difference varies by age:
- Young adults (< 40 years): 12-15 ms longer in women
- Middle-aged adults (40-69 years): 6-10 ms longer in women
- Older adults (≥ 70 years): Gender difference becomes minimal and practically disappears
More recent research suggests age-specific refinements may be warranted. One large study of 57,595 subjects proposed slightly lower thresholds for younger women (440 ms for age < 40 years, 450 ms for age 40-69 years, and 460 ms for age ≥ 70 years). 3 However, the guideline-recommended threshold of 460 ms remains the standard clinical cutoff across all adult age groups for simplicity and consistency. 122
Critical Clinical Pitfalls
Bazett's formula (QTc = QT/√RR) should be avoided as it produces falsely prolonged QTc values, particularly at higher heart rates, and has significantly wider distributions than other correction formulas. 4 This can lead to 30% of normal ECGs being misclassified as abnormal if using a 440 ms threshold with Bazett's formula. 4
Preferred correction formulas that minimize rate-dependency include:
- Linear function of RR interval
- Fridericia formula (exponent 0.33)
- Framingham or Hodges formulas
When measuring QTc, exclude U-waves from the measurement to avoid falsely elevated values—prominent U-waves do not represent true QT prolongation. 5
Clinical Significance
Women with prolonged QTc (> 460 ms) face increased risk of:
- Malignant ventricular arrhythmias
- Sudden cardiac death (2.5-fold increased risk) 6
- Drug-induced torsades de pointes
The FDA recommends monitoring for three severity levels when evaluating drug effects: > 450 ms, > 480 ms, and > 500 ms. 1